Evaluation of the ovarian reserve function in patients with metabolic syndrome in relation to healthy controls and different age groups

Journal of Ovarian Research

Betul Usluogullari¹  Oguz Kaan Unal⁴  Celil Alper Usluogullari³  Nurcan Cetin²  Fevzi Balkan⁴ 

[1] Gynecology and Obstetrics Department, Cengiz Gokcek State Hospital, Gaziantep, Turkey;Radiology Department, Aksaray State Hospital, Aksaray, Turkey;Endocrinology and Metabolic Disease, Dr. Ersin Arslan State Hospital, Gaziantep, Turkey;Endocrinology and Metabolic Disease, Aksaray State Hospital, Aksaray, Turkey

关键词: Gonadotropins;    Obesity;    Antral follicle;    Ovarian volume;    Ovarian reserve;    Metabolic syndrome;   

Others  :  801053
DOI  :  10.1186/1757-2215-7-63

 received in 2014-04-12, accepted in 2014-06-04,  发布年份 2014

【 摘 要 】

Objective

To evaluate the ovarian reserve function in female patients with metabolic syndrome (MetS).

Methods

This study evaluated 136 subjects, 67 with MetS and 69 controls. Subjects were divided into three age groups. Group I included 49 subjects aged 20–29 years, 22 with MetS and 27 controls; group II included 45 subjects aged 30–39 years, 22 with MetS and 23 controls; and group III included 42 subjects aged 40–49 years, 23 with MetS and 19 controls. Demographic characteristics, anthropometrics, blood biochemistry, and gonadotrophic hormones were compared as total ovarian volume and antral follicle count on ovarian transvaginal ultrasonography.

Results

Serum levels of FSH, LH, E2 and progesterone were similar in the MetS and control groups, while testosterone levels were significantly higher in MetS patients than controls, both in the overall population (p = 0.024) and in those aged 20–29 years (p = 0.018). Total ovarian volume was significantly lower in MetS patients than controls, in both the overall population (p = 0.003) and those aged 20–29 years (p = 0.018), while antral follicle counts were similar. Ovarian volume correlated positively with antral follicle count (AFC) (r = 0.37; p < 0.001) and negatively with age (r = 0.34; p < 0.001) and FSH concentration (r = 0.21; p = 0.013). AFC was negatively correlated with age (r = 0.36; p < 0.001).

Conclusion

Ovarian reserve function is significantly lower in MetS patients than in healthy control subjects, particularly in women aged 20–29 years.

【 授权许可】

   
2014 Balkan et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Isik S, Ozcan HN, Ozuguz U, Tutuncu YA, Berker D, Alimli AG, Akbaba G, Karademir MA, Guler S: Evaluation of ovarian reserve based on hormonal parameters, ovarian volume, and antral follicle count in women with type 2 diabetes mellitus. J Clin Endocrinol Metab 2012, 97:261-269.
• [2]Bulun SE, Adashi EY: The physiology and pathology of the female reproduction axis. In Williams textbook of endocrinology. 10th edition. Edited by Larson PR, Kronenberg HM, Melmed S, Polonsky KS. Philadelphia, PA: Elsevier Science; 2003:587-664.
• [3]Templeton A, Morris JK, Parslow W: Factors that affect outcome of in vitro fertilisation treatment. Lancet 1996, 348:1402-1406.
• [4]Lass A, Skull J, McVeigh E, Margara R, Winston RM: Measurement of ovarian volume by transvaginal sonography before ovulation induction with human menopausal gonadotrophin for in vitro fertilization can predict poor response. Hum Reprod 1997, 12:294-297.
• [5]Hendriks DJ, Kwee J, Mol BW, te Velde ER, Broekmans FJ: Ultrasonography as a tool for the prediction of outcome in IVF patients: a comparative meta-analysis of ovarian volume and antral follicle count. Fertil Steril 2007, 87:764-775.
• [6]Hendriks DJ, Mol BW, Bancsi LF, TeVelde ER, Broekmans FJ: Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle stimulating hormone level. Fertil Steril 2005, 83:291-301.
• [7]Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB: A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 2006, 12:685-718.
• [8]Reaven GM: Banting lecture. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
• [9]Hu G, Qiao Q, Tuomilehto J: The metabolic syndrome and cardiovascular risk. Curr Diabetes Rev 2005, 1:137-143.
• [10]Masheshwari A, Stofberg L, Bhattacharya S: Effect of overweight and obesity on assisted reproductive technology – a systematic review. Hum Reprod Update 2007, 13:433-444.
• [11]Jungheim ES, Travieso JL, Carson KR, Moley KH: Obesity and reproductive function. Obstet Gynecol Clin North Am 2012, 39:479-493.
• [12]Bleil ME, Gregorich SE, McConnell D, Rosen MP, Cedars MI: Does accelerated reproductive aging underlie premenopausal risk for cardiovascular disease? Menopause 2013, 20:1139-1146.
• [13]Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001, 285:2486-2497.
• [14]Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
• [15]Gokcel A, Ozsahin AK, Sezgin N, Karakose H, Ertorer ME, Akbaba M, Baklaci N, Sengul A, Guvener N: High prevalence of diabetes in Adana, a southern province of Turkey. Diabetes Care 2003, 26:3031-3034.
• [16]Shifren JL, Schiff I: The aging ovary. J Womens Health Gend Based Med 2000, 1:S3-S7.
• [17]Yeshaya A, Orvieto R, Dicker D, Karp M, Ben-Rafael Z: Menstrual characteristics of women suffering from insulin-dependent diabetes mellitus. Int J Fertil Menopausal Stud 1995, 40:269-273.
• [18]Dorman JS, Steenkiste AR, Foley TP, Strotmeyer ES, Burke JP, Kuller LH: Familial Autoimmune and Diabetes (FAD) Study. Menopause in type 1 diabetic women: is it premature? Diabetes 2001, 50:1857-1862.
• [19]Köşüş N, Köşüş A, Turhan NÖ, Kamalak Z: Do threshold values of ovarian volume and follicle number for diagnosing polycystic ovarian syndrome in Turkish women differ from western countries? Eur J Obstet Gynecol Reprod Biol 2011, 154:177-181.
• [20]Erdem M, Erdem A, Biberoglu K, Arslan M: Age-related changes in ovarian volume, antral follicle counts and basal follicle stimulating hormone levels: comparison between fertile and infertile women. Gynecol Endocrinol 2003, 17:199-205.
• [21]Syrop CH, Willhoite A, Van Voorhis BJ: Ovarian volume: a novel outcome predictor for assisted reproduction. Fertil Steril 1995, 64:1167-1171.
• [22]Kupesic S, Kurjak A, Bjelos D, Vujisic S: Three-dimensional ultrasonographic ovarian measurements and in vitro fertilization outcome are related to age. Fertil Steril 2003, 79:190-197.
• [23]Oppermann K, Fuchs SC, Spritzer PM: Ovarian volume in pre- and perimenopausal women: a population-based study. Menopause 2003, 10:209-213.
• [24]Malhotra N, Bahadur A, Singh N, Kalaivani M, Mittal S: Does obesity compromise ovarian reserve markers? A clinician’s perspective. Arch Gynecol Obstet 2013, 287:161-166.
• [25]Ng EH, Yeung WS, Fong DY, Ho PC: Effects of age on hormonal and ultrasound markers of ovarian reserve in Chinese women with proven fertility. Hum Reprod 2003, 18:2169-2174.
• [26]Chang MY, Chiang CH, Chiu TH, Hsieh TT, Soong YK: The antral follicle count predicts the outcome of pregnancy in a controlled ovarian Hyperstimulation/intrauterine insemination program. J Assist Reprod Genet 1998, 15:12-17.
• [27]Metwally M, Cutting R, Tipton A, Skull J, Ledger WL, Li TC: Effect of increased body mass index on oocyte and embryo quality in IVF patients. Reprod Biomed Online 2007, 15:532-538.
• [28]Van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD: Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996, 347:714-718.
• [29]Zhang HY, Guo CX, Zhu FF, Qu PP, Lin WJ, Xiong J: Clinical characteristics, metabolic features, and phenotype of Chinese women with polycystic ovary syndrome: a large-scale case–control study. Arch Gynecol Obstet 2013, 287:525-531.
• [30]Brewer CJ, Balen AH: The adverse effects of obesity on conception and implantation. Reproduction 2010, 140:47-364.
• [31]Wojciechowski P, Lipowska A, Rys P, Ewens KG, Franks S, Tan S, Lerchbaum E, Vcelak J, Attaoua R, Straczkowski M, Azziz R, Barber TM, Hinney A, Obermayer-Pietsch B, Lukasova P, Bendlova B, Grigorescu F, Kowalska I, Goodarzi MO, Strauss JF 3rd, McCarthy MI, Malecki MT, GIANT Consortium: Impact of FTO genotypes on BMI and weight in polycystic ovary syndrome: a systematic review and meta-analysis. Diabetologia 2012, 55:636-2645.
• [32]Ding EL, Song Y, Malik VS, Liu S: Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006, 295:1288-1299.
• [33]Wang JX, Davies M, Norman RJ: Body mass and probability of pregnancy during assisted reproduction treatment: retrospective study. BMJ 2000, 321:1320-1321.